Carlo Albera

Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement

Robert P. Baughman, Marjolein Drent, Mani S. Kavuru et al. · American Journal of Respiratory and Critical Care Medicine · 2006 · 702 citations

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

Luca Richeldi, Evans R. Fernández Pérez, Ulrich Costabel et al. · The Lancet Respiratory Medicine · 2019 · 275 citations

Fibrosis, Antifibrotic Therapy, Inflammatory Lung Disease +10

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial

Dinesh Khanna, Carlo Albera, Aryeh Fischer et al. · The Journal of Rheumatology · 2016 · 262 citations · Full text

Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis

Marc A. Judson, Robert P. Baughman, Ulrich Costabel et al. · European Respiratory Journal · 2014 · 210 citations

Clinical Immunology, Major Secondary End-points, Inflammatory Lung Disease +24

Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Jürgen Behr, Elisabeth Bendstrup, Bruno Crestani et al. · The Lancet Respiratory Medicine · 2016 · 162 citations

Idiopathic Pulmonary Fibrosis, Pharmacology, Pulmonary Pharmacology +5